About Auristone

Auristone is an Asian-based epigenomic profiling company with data analytics capabilities that spun out from Genome Institute of Singapore (GIS) in 2021 with the vision to be the largest curator of Asian Epigenomic database to drive epigenomic discoveries. The company’s Scientific Co-Founders are Professor Patrick Tan and Professor Teh Bin Tean, who are both internationally recognised world-experts in the field of epigenomics and Gastric Cancer (GC), and in the field of genomic, translational research and drug discovery respectively.

Auristone seeks to impact Personalised Medicine for cancer patients by introducing EPI-Call™, a 2nd generation NGS test where epigenomic information is provided in addition to genomic information. Auristone also develops predictive algorithms for patient response to treatment types. Beyond EPI-Call™, Auristone aims to utilise her proprietary Epigenomic-driven Discovery Engine (Epi-Tome™) to guide novel biomarkers and drug targets discoveries through both in-house R&D and external partnerships.

With improved precision oncology through EPI-Call™ and EPI-Tome™, we are one step closer to providing bespoke therapy, reducing side-effects, lower costs and better quality of life for our patients.

Job Description

This project aims to integrate epigenomic profiling into clinical practice to advance precision medicine and enhance patient care with our flagship product EPI-CALL. Epigenomic profiling offers valuable insights into gene expression regulation, tumour microenvironment and treatment response, allowing for tailored therapeutic interventions and improved patient outcomes.

• Early adoption of Epigenomic Profiling: The main highlight of this project is the integration of epigenomic profiling technologies into routine clinical workflows with genomic testing. This involves collaborating with partners and clinicians to introduce EPI-CALL and gather feedback on the results on its clinical utility.
• Patient Care Enhancement: The primary responsibility is to leverage on our proprietary pipeline that generates outcomes to personalise treatment strategies and optimise patient care pathways. This includes identifying biomarkers, predicting treatment responses, and monitoring disease progression through epigenetic signatures.

Responsibilities

• Market Analysis: Conduct a thorough analysis of the clinical landscape to identify opportunities and challenges for EPI-CALL.
• Stakeholder Engagement: Collaborate with healthcare providers, researchers, and regulatory bodies to garner support and establish guidelines for epigenomic testing in clinical settings.
• Protocol & Workflow Development: Develop standardised protocols for sample collection, processing, and analysis to ensure consistency and reproducibility of epigenomic data.
• Education and Training: Provide education and training sessions for healthcare professionals on the principles and applications of epigenomic profiling in patient care.
• Clinical Interpretation: Utilise bioinformatics tools and resources to interpret epigenomic data and translate findings from EPI-CALL into actionable insights for clinical decision-making.